San Diego, CA – Cortechs.ai, a global leader in AI-powered quantitative imaging solutions for radiology and neurology, is proud to announce a strategic distribution partnership with RMS Medical Devices, a premier provider of innovative medical technologies based in Belgium. This collaboration marks a significant milestone in Cortechs.ai’s continued expansion across Europe and will bring its cutting-edge imaging solutions to healthcare providers in Belgium, the Netherlands, and Luxembourg (Benelux).
As demand for advanced diagnostic tools continues to grow, the partnership will allow RMS Medical Devices to offer Cortechs.ai’s suite of clinically validated AI software — such as NeuroQuant®, NeuroQuant® MS, and OnQ Prostate — to its expansive customer network. These tools enable more accurate, consistent, and efficient analysis of neuroimaging, supporting improved clinical decision-making and patient outcomes.
“Partnering with RMS Medical Devices represents a critical step in our mission to deliver AI-powered healthcare solutions globally,” said Daniel D’Amour, Director of Global Partnerships at Cortechs.ai. “RMS’s deep expertise in clinical implementation, strong customer relationships, and proven success with advanced imaging technologies make them the ideal partner to champion our products in the Benelux region.”
“At RMS Medical Devices, we are constantly seeking technologies that elevate patient care and improve clinical outcomes,” said Olivier Wouters, Director of Business and Product Development at RMS Medical Devices. “Cortechs.ai’s advanced AI applications align perfectly with our mission to deliver meaningful innovation to the Benelux healthcare landscape. We’re proud to integrate these solutions into our portfolio and look forward to supporting clinicians in leveraging AI for more precise and efficient neuroimaging analysis.”
By combining Cortechs.ai’s innovation in neuroimaging AI with RMS’s trusted distribution infrastructure and support services, the two companies aim to accelerate adoption and maximize clinical impact. Healthcare professionals across the Benelux region will now have access to state-of-the-art solutions that deliver actionable insights from complex imaging data — improving early detection, treatment planning, and disease monitoring.
For more information about Cortechs.ai and RMS Medical Devices, visit https://www.cortechs.ai/ and https://www.rmsmedicaldevices.com/.
About Cortechs.ai
Cortechs.ai is a leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and early detection, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical device software that provides quantitative MR imaging analysis to assist clinicians in assessing neurodegeneration, as well as brain and prostate cancer. Cortechs.ai’s industry-leading imaging solutions offer radiologists, oncologists, and urologists a streamlined, cost-effective way to assess brain and prostate health, including cancer evaluation. The company also offers FDA-cleared products for evaluating neurological disorders such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, tumors, and other brain abnormalities. For more information, please visit www.cortechs.ai and follow us on Twitter, LinkedIn, and Facebook.
